SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

FDC jumps on launching two variants of Favipiravir drug for Covid-19

26 Aug 2020 Evaluate

FDC is currently trading at Rs. 332.45, up by 14.95 points or 4.71% from its previous closing of Rs. 317.50 on the BSE.

The scrip opened at Rs. 326.30 and has touched a high and low of Rs. 336.95 and Rs. 326.30 respectively. So far 39516 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 354.00 on 10-Aug-2020 and a 52 week low of Rs. 152.50 on 15-Oct-2019.

Last one week high and low of the scrip stood at Rs. 336.95 and Rs. 314.15 respectively. The current market cap of the company is Rs. 5428.40 crore.

The promoters holding in the company stood at 69.24%, while Institutions and Non-Institutions held 10.42% and 20.34% respectively.

FDC has launched two variants of the COVID-19 drug, Favipiravir - PiFLU and Favenza - which will be used to treat mild to moderate cases of COVID-19 in India. The company’s PiFLU and Favenza is currently available across the country. Earlier this year, the Drug Controller General of India (DCGI) approved the use of Favipiravir, an off patent, oral anti-viral drug that has been shown to quicken clinical recovery in COVID-19 patients with mild to moderate symptoms. It is a broad spectrum anti-viral agent, and selectively inhibits RNA polymerase of influenza and SARCOV-2 virus and prevents viral replication.

Besides, the company has also increased the production and availability of its brand of balanced electrolyte drink ‘Enerzal and Electral as according to ASPEN guidelines, 03 litres of fluid intake in a day (60 to 120 ml in every 30 min) helps in speedy recovery of people who are home quarantined.

FDC is engaged in manufacture of specialized formulations, and oral rehydration salts (ORS).

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: